FDA Advisers Back Lilly's Alzheimer's Drug
A U.S. FDA advisory committee has unanimously endorsed Eli Lilly's Alzheimer's drug, donanemab, signaling a major breakthrough for patients with early-stage disease. This promising treatment, which effectively slows cognitive decline by clearing amyloid plaques, now awaits the FDA's final regulatory decision later this year.